A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis-Reference-Cited by-同舟云学术

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

Published:2013 Issue:5 Volume:15 Page:R164
ISSN:1478-6354
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Martin David A,Churchill Melvin,Flores-Suarez Luis,Cardiel Mario H,Wallace Daniel,Martin Richard,Phillips Kristine,Kaine Jeffrey L,Dong Hua,Salinger David,Stevens Erin,Russell Chris B,Chung James B

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference16 articles.

1. The Pathogenesis of Rheumatoid Arthritis

2. Updated recommendations for the treatment of rheumatoid arthritis: Another step on a long road

3. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

4. Recent advances in the IL-17 cytokine family

5. Interleukin-17 and Type 17 Helper T Cells

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the role of IL-17: Therapeutic insights and cardiovascular implications;Cytokine & Growth Factor Reviews;2024-06

2. From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?;Expert Opinion on Investigational Drugs;2024-05-09

3. Liposomes: An Emerging Strategy for the Effective Treatment of Rheumatoid Arthritis;Current Rheumatology Reviews;2024-03-04

4. The IL-17 family in diseases: from bench to bedside;Signal Transduction and Targeted Therapy;2023-10-11

5. Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion;Frontiers in Immunology;2023-09-19